STOCK TITAN

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences

Nuvation Bio (NYSE: NUVB) has announced an upcoming presentation of new comparative data for taletrectinib versus crizotinib in treating ROS1-positive non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress 2025 in Paris.

The research, featuring a matching-adjusted indirect comparison study, will be presented by Dr. Misako Nagasaka, Associate Professor at UCI School of Medicine's Division of Hematology and Oncology. The mini oral presentation, numbered LBA2, is scheduled for March 27, 2025, from 4:00 p.m. to 5:05 p.m. CET (11:00 a.m. to 12:05 p.m. ET).

The presentation materials will be subsequently available in the Publications section of Nuvation Bio's website.

Nuvation Bio (NYSE: NUVB) ha annunciato una prossima presentazione di nuovi dati comparativi per taletrectinib rispetto a crizotinib nel trattamento del carcinoma polmonare non a piccole cellule positivo per ROS1 (NSCLC) al Congresso Europeo sul Cancro del Polmone 2025 a Parigi.

La ricerca, che presenta uno studio di confronto indiretto aggiustato per abbinamento, sarà presentata dalla Dr.ssa Misako Nagasaka, Professoressa Associata presso la Divisione di Ematologia e Oncologia della Scuola di Medicina UCI. La presentazione orale mini, contrassegnata come LBA2, è programmata per il 27 marzo 2025, dalle 16:00 alle 17:05 CET (11:00 - 12:05 ET).

I materiali della presentazione saranno successivamente disponibili nella sezione Pubblicazioni del sito web di Nuvation Bio.

Nuvation Bio (NYSE: NUVB) ha anunciado una próxima presentación de nuevos datos comparativos para taletrectinib frente a crizotinib en el tratamiento del cáncer de pulmón no microcítico positivo para ROS1 (NSCLC) en el Congreso Europeo de Cáncer de Pulmón 2025 en París.

La investigación, que presenta un estudio de comparación indirecta ajustado por coincidencia, será presentada por la Dr. Misako Nagasaka, Profesora Asociada en la División de Hematología y Oncología de la Escuela de Medicina de UCI. La presentación oral breve, numerada LBA2, está programada para el 27 de marzo de 2025, de 16:00 a 17:05 CET (11:00 a 12:05 ET).

Los materiales de la presentación estarán disponibles posteriormente en la sección de Publicaciones del sitio web de Nuvation Bio.

누베이션 바이오 (NYSE: NUVB)는 ROS1 양성 비소세포 폐암 (NSCLC) 치료를 위한 탈레트렉티닙과 크리조티닙의 비교 데이터를 유럽 폐암 학회 2025에서 발표할 예정이라고 발표했습니다. 이 발표는 파리에서 진행됩니다.

연구는 매칭 조정 간접 비교 연구를 특징으로 하며, 미사코 나가사카 박사가 UCI 의과대학 혈액학 및 종양학 부교수로서 발표할 예정입니다. 미니 구두 발표는 LBA2로 번호가 매겨져 있으며, 2025년 3월 27일 오후 4시부터 5시 5분까지 CET (오전 11시부터 오후 12시 5분까지 ET)로 예정되어 있습니다.

발표 자료는 이후 누베이션 바이오 웹사이트의 출판 섹션에서 확인할 수 있습니다.

Nuvation Bio (NYSE: NUVB) a annoncé une prochaine présentation de nouvelles données comparatives pour taletrectinib par rapport à crizotinib dans le traitement du cancer du poumon non à petites cellules positif pour ROS1 (NSCLC) lors du Congrès Européen sur le Cancer du Poumon 2025 à Paris.

La recherche, qui présente une étude de comparaison indirecte ajustée, sera présentée par Dr. Misako Nagasaka, Professeur Associé à la Division d'Hématologie et d'Oncologie de l'École de Médecine de l'UCI. La présentation orale courte, numérotée LBA2, est prévue pour le 27 mars 2025, de 16h00 à 17h05 CET (11h00 à 12h05 ET).

Les matériaux de présentation seront ensuite disponibles dans la section Publications du site Web de Nuvation Bio.

Nuvation Bio (NYSE: NUVB) hat eine bevorstehende Präsentation neuer Vergleichsdaten für Taletrectinib im Vergleich zu Crizotinib bei der Behandlung von ROS1-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) beim Europäischen Lungenkrebs-Kongress 2025 in Paris angekündigt.

Die Forschung, die eine anpassungsbereinigte indirekte Vergleichsstudie umfasst, wird von Dr. Misako Nagasaka, außerordentliche Professorin an der UCI School of Medicine, Abteilung für Hämatologie und Onkologie, präsentiert. Die Mini-Mundpräsentation mit der Nummer LBA2 ist für den 27. März 2025 von 16:00 bis 17:05 Uhr MEZ (11:00 bis 12:05 Uhr ET) geplant.

Die Präsentationsmaterialien werden anschließend im Publikationsbereich der Website von Nuvation Bio verfügbar sein.

Positive
  • None.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France.

Mini Oral Presentation Overview:

Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison
Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine
Date: Thursday, March 27, 2025
Session Time: 4:00 p.m. – 5:05 p.m. CET / 11:00 a.m. – 12:05 p.m. ET
Session: Mini Oral Session 1
Presentation Number: LBA2

The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation.

About Taletrectinib

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.

Based on pooled results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio’s NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China’s NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.

About Nuvation Bio

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com or follow the Company on LinkedIn and X (@nuvationbioinc).

Nuvation Bio Investor Contact:

ir@nuvationbio.com



Nuvation Bio Media Contact:

media@nuvationbio.com

Source: Nuvation Bio Inc.

FAQ

When will Nuvation Bio (NUVB) present the taletrectinib comparison data at ELCC 2025?

Nuvation Bio will present the data on March 27, 2025, from 4:00-5:05 p.m. CET during Mini Oral Session 1.

What type of cancer treatment is NUVB's taletrectinib being compared to?

Taletrectinib is being compared to crizotinib in treating ROS1-positive non-small cell lung cancer (NSCLC).

Who will present NUVB's taletrectinib comparison study at ELCC 2025?

Dr. Misako Nagasaka, Associate Professor from UCI School of Medicine's Division of Hematology and Oncology, will present the study.

Where can investors find NUVB's taletrectinib presentation materials after the ELCC event?

The presentation materials will be available in the Publications section of Nuvation Bio's website after the presentation.
Nuvation Bio Inc

NYSE:NUVB

NUVB Rankings

NUVB Latest News

NUVB Stock Data

552.05M
247.55M
26.68%
58.95%
7.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO